Isomorphic Labs, an AI-for-drug-discovery company that emerged from Google DeepMind, is raising over $2 billion in a new funding round, with Thrive Capital leading the investment and Alphabet also participating. This funding event underlines the strong connections between Isomorphic Labs and its origins at DeepMind, as it seeks to advance its mission of leveraging AI in the drug discovery process. Thrive Capital is known for its focus on high-impact AI and biotech ventures, aiming to drive transformative technologies in these sectors.

Alphabet: Alphabet is the parent company of Google and its subsidiaries, including DeepMind, with investments spanning AI, cloud computing, and life sciences. It fosters innovation through its venture arms and direct participations. Alphabet is participating as an investor in Isomorphic Labs’ latest funding round.
Thrive Capital: Thrive Capital is a venture capital firm investing in technology, internet, and life sciences companies at various stages. It supports founders building category-defining businesses in AI and biotech. Thrive Capital is leading the funding round for Isomorphic Labs.
Isomorphic Labs: Isomorphic Labs is an AI-for-drug-discovery company that applies advanced artificial intelligence to accelerate the development of new medicines. It was spun out from Google DeepMind to focus exclusively on biology and pharmaceutical applications. The company is raising more than $2 billion in a new funding round led by Thrive Capital with participation from Alphabet.

`json
{
“DeepMind Connection”: “The funding highlights the ongoing relationship between Isomorphic Labs and its origins with DeepMind under Alphabet.”,
“Spin-out Background”: “Isomorphic Labs was established from Google DeepMind to independently focus on AI applications in drug discovery.”,
“Lead Investor Strategy”: “Thrive Capital focuses on ventures in AI and biotech that aim to drive technological transformation.”
}
`